drugset / Trial / NCT06342947
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
RandomizedSingle-groupTriple-blindTreatment
Summary
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-08-19
- Completion
- 2024-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALG-055009 | Unknown | 0.3 mg | Oral |
| Subject | ALG-055009 | Unknown | 0.5 mg | Oral |
| Subject | ALG-055009 | Unknown | 0.7 mg | Oral |
| Subject | ALG-055009 | Unknown | 0.9 mg | Oral |